Tobira is seeking in-licensing and combination therapy development partners for our therapies in fibrosis, inflammation and HIV.
Please direct Corporate Development inquiries to:
In April 2016, Tobira entered into license agreements with Dong-A ST. Ltd.
Tobira acquired the exclusive rights to develop and market evogliptin in the United States, Canada, Europe and Australia.
Dong-A received an exclusive license to develop and market CVC in the Republic of Korea.